A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase
Open accessThe DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The quinoline-based allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are promising candidates for clinically useful antiviral agents. Studies using these compounds have highlighted the role of IN in both early and late stages of virus replication. However, dissecting the exact mechanism of action of the quinoline-based ALLINIs has been complicated by the multifunctional nature of these inhibitors because they both inhibit IN binding with its cofactor LEDGF/p75 and promote aberrant IN multimerization with similar potencies in vitro. Here we report design of small molecules that allowed us to probe the role of HIV-1 IN multimerization independently from IN-LEDGF/p75 interactions in infected cells. We altered the rigid quinoline moiety in ALLINIs and designed pyridine-based molecules with a rotatable single bond to allow these compounds to bridge between interacting IN subunits optimally and promote oligomerization. The most potent pyridine-based inhibitor, KF116, potently (EC50 of 0.024 µM) blocked HIV-1 replication by inducing aberrant IN multimerization in virus particles, whereas it was not effective when added to target cells. Furthermore, KF116 inhibited the HIV-1 IN variant with the A128T substitution, which confers resistance to the majority of quinoline-based ALLINIs. A genome-wide HIV-1 integration site analysis demonstrated that addition of KF116 to target or producer cells did not affect LEDGF/p75-dependent HIV-1 integration in host chromosomes, indicating that this compound is not detectably inhibiting IN-LEDGF/p75 binding. These findings delineate the significance of correctly ordered IN structure for HIV-1 particle morphogenesis and demonstrate feasibility of exploiting IN multimerization as a therapeutic target. Furthermore, pyridine-based compounds present a novel class of multimerization selective IN inhibitors as investigational probes for HIV-1 molecular biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Counterintuitively, the underlying mode of ALLINI action is not via inhibition of integration140,142,174–177,179–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MINI compounds moreover were ineffective at inhibiting the early stage of HIV-1 infection177.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“The common biochemical consequence of ALLINI binding is aberrant HIV-1 IN hyper-multimerization140,142,174–181.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“Compounds of the latter class do not effectively antagonise HIV-1 IN-LEDGF/p75 binding.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“Consistent with the known role of LEDGF/p75 in HIV-1 integration targeting, genic integration targeting during HIV-1 ingress was suppressed by ALLINIs177,184,185.”
From Structure and function of retroviral integrase (2022) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915 · cited 1×
“Coot program [65] was used for the subsequent refinement and building of the structure.”
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742 · cited 1×
“Refmac5 [66] of the CCP4 package was used for the restraint refinement.”
MethodIn Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
Berne, B. J., & Pecora, R. (1976) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,856
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834 · cited 1×
“Replication competent HIV-1 was generated using pNL4-3 [68].”
MethodHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832 · cited 3×
“Since LEDGF/p75 is the primary cellular factor responsible for targeting HIV-1 integration to actively transcribed units [58,59], our findings indicate that the treatment of target cells with GS-B likely inhibits IN-LEDGF/p75 binding in the infected cells.”
BackgroundSelf-citationConnor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion
Painter, J., & Merritt, E. A. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906005270 · Cited by 1,240
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810 · cited 2×
“The crystal structure of the catalytic core domain of HIV-1 IN [62] (PDB # 1ITG) was used as a starting model.”
MethodHIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells
Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., & Debyser, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209278200 · Cited by 704
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
A role for LEDGF/p75 in targeting HIV DNA integration
Ciuffi, A., Llano, M., Poeschla, E., Hoffmann, C., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. (2005) · Nature Medicine · doi:10.1038/nm1329 · Cited by 658
Self-citationAn essential role for LEDGF/p75 in HIV integration
Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., Teo, W., & Poeschla, E. M. (2006) · Science · doi:10.1126/science.1132319 · Cited by 537
Self-citationYan, N., Regalado-Magdos, A. D., Stiggelbout, B., Lee-Kirsch, M. A., & Lieberman, J. (2010) · Nature Immunology · doi:10.1038/ni.1941 · Cited by 529 · cited 2×
“Viral genomic RNA stability assay The stability of incoming viral genomic RNA was measured as described previously [84] with minor modifications.”
MethodLEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479 · cited 4×
“In particular, A128T substitution is most common and has been shown to confer marked resistance to the majority of ALLINIs [32,35,39,40].”
BackgroundInfluentialShun, M.-C., Raghavendra, N. K., Vandegraaff, N., Daigle, J. E., Hughes, S., Kellam, P., Cherepanov, P., & Engelman, A. (2007) · Genes & Development · doi:10.1101/gad.1565107 · Cited by 467
Wang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C., & Bushman, F. D. (2007) · Genome Research · doi:10.1101/gr.6286907 · Cited by 457 · cited 1×
“Isolation of integration sites using 454-pyrosequencing Isolation of HIV-1 integration sites was performed using ligation-mediated PCR as previously described [75,76] with some changes.”
MethodSelf-citationMultiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
Engelman, A., Englund, G., Orenstein, J. M., Martin, M. A., & Craigie, R. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2729-2736.1995 · Cited by 445
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408 · cited 1×
“LEDGF/IBD bound to HIV-1 IN CCD dimers [13,33] shows that”
BackgroundChen, J. C.-H., Krucinski, J., Miercke, L. J. W., Finer-Moore, J. S., Tang, A. H., Leavitt, A. D., & Stroud, R. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150220297 · Cited by 404
Jachimska, B., Wasilewska, M., & Adamczyk, Z. (2008) · Langmuir · doi:10.1021/la800548p · Cited by 377 · cited 1×
“Since the diffusion coefficient depends on the particle size and shape, DLS can be used to study particle aggregation [51,53,54].”
MethodPradeepa, M. M., Sutherland, H. G., Ule, J., Grimes, G. R., & Bickmore, W. A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002717 · Cited by 349
Wang, J.-Y. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7333 · Cited by 335
A Soluble Active Mutant of HIV-1 Integrase
Jenkins, T. M., Engelman, A., Ghirlando, R., & Craigie, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7712 · Cited by 271
HIV Integration Targeting: A Pathway Involving Transportin-3 and the Nuclear Pore Protein RanBP2
Ocwieja, K. E., Brady, T. L., Ronen, K., Huegel, A., Roth, S. L., Schaller, T., James, L. C., Towers, G. J., Young, J. A. T., Chanda, S. K., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001313 · Cited by 212 · cited 1×
“Isolation of integration sites using 454-pyrosequencing Isolation of HIV-1 integration sites was performed using ligation-mediated PCR as previously described [75,76] with some changes.”
MethodSelf-citationThe Interaction of LEDGF/p75 with Integrase Is Lentivirus-specific and Promotes DNA Binding
Busschots, K., Vercammen, J., Emiliani, S., Benarous, R., Engelborghs, Y., Christ, F., & Debyser, Z. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411681200 · Cited by 208
Structural basis for high-affinity binding of LEDGF PWWP to mononucleosomes
Eidahl, J. O., Crowe, B. L., North, J. A., McKee, C. J., Shkriabai, N., Feng, L., Plumb, M., Graham, R. L., Gorelick, R. J., Hess, S., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt074 · Cited by 207
Self-citationNobbmann, U., Connah, M., Fish, B., Varley, P., Gee, C., Mulot, S., Chen, J., Zhou, L., Lu, Y., Sheng, F., et al. (2007) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2007.10648095 · Cited by 205 · cited 1×
“Since the diffusion coefficient depends on the particle size and shape, DLS can be used to study particle aggregation [51,53,54].”
MethodJurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300703110 · Cited by 203 · cited 8×
“This multimodal mechanism of action of ALLINIs concordantly resulted in cooperative inhibition of HIV-1 replication in cell culture [33,38].”
BackgroundMethodInfluentialSelf-citationSelection of Target Sites for Mobile DNA Integration in the Human Genome
Berry, C., Hannenhalli, S., Leipzig, J., & Bushman, F. D. (2006) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0020157 · Cited by 201 · cited 2×
“The analysis and statistical methods for HIV-1 integration site distribution have been previously described [77].”
MethodSelf-citationSt Gelais, C., de Silva, S., Amie, S. M., Coleman, C. M., Hoy, H., Hollenbaugh, J. A., Kim, B., & Wu, L. (2012) · Retrovirology · doi:10.1186/1742-4690-9-105 · Cited by 191 · cited 1×
“qPCR analysis Levels of HIV-1 early reverse transcription products, late reverse transcription products (LRT), 2-LTR circles and integrated proviruses (Alu-PCR reactions) were quantified using primers, probes, and qPCR conditions described previously [71,72].”
MethodSelf-citationMultimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors
Kessl, J. J., Jena, N., Koh, Y., Taskent-Sezgin, H., Slaughter, A., Feng, L., de Silva, S., Wu, L., Le Grice, S. F. J., Engelman, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.354373 · Cited by 182 · cited 15×
“HTRF-based IN multimerization and IN-LEDGF/p75 binding assays were carried out as described previously [33].”
BackgroundMethodInfluentialSelf-citationInhibiting HIV-1 integrase by shifting its oligomerization equilibrium
Hayouka, Z., Rosenbluh, J., Levin, A., Loya, S., Lebendiker, M., Veprintsev, D., Kotler, M., Hizi, A., Loyter, A., & Friedler, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700781104 · Cited by 181
In Vivo Analysis of Retroviral Integrase Structure and Function
Engelman, A. (1999) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60309-7 · Cited by 176
Christ, F., Shaw, S., Demeulemeester, J., Desimmie, B. A., Marchand, A., Butler, S., Smets, W., Chaltin, P., Westby, M., Debyser, Z., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00717-12 · Cited by 176
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action
Tsiang, M., Jones, G. S., Niedziela-Majka, A., Kan, E., Lansdon, E. B., Huang, W., Hung, M., Samuel, D., Novikov, N., Xu, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347534 · Cited by 167 · cited 8×
“Previous reports have shown that addition of GS-B to target cells does not affect reverse transcription but blocks HIV-1 integration [35,41].”
BackgroundResultInfluentialHare, S., Shun, M.-C., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000259 · Cited by 166
van Nuland, R., van Schaik, F. M., Simonis, M., van Heesch, S., Cuppen, E., Boelens, R., Timmers, H. M., & van Ingen, H. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-12 · Cited by 166
Retroviral DNA integration: HIV and the role of LEDGF/p75
Ciuffi, A., & Bushman, F. D. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.05.006 · Cited by 152 · cited 3×
“Since LEDGF/p75 is the primary cellular factor responsible for targeting HIV-1 integration to actively transcribed units [58,59], our findings indicate that the treatment of target cells with GS-B likely inhibits IN-LEDGF/p75 binding in the infected cells.”
BackgroundSelf-citationLens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration
Ferris, A. L., Wu, X., Hughes, C. M., Stewart, C., Smith, S. J., Milne, T. A., Wang, G. G., Shun, M.-C., Allis, C. D., Engelman, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914142107 · Cited by 141
LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions
Desimmie, B. A., Schrijvers, R., Demeulemeester, J., Borrenberghs, D., Weydert, C., Thys, W., Vets, S., Van Remoortel, B., Hofkens, J., De Rijck, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-57 · Cited by 139 · cited 3×
“Strikingly, RNPs were mislocalized between the core and viral membrane [38,41,42].”
BackgroundMcKee, C. J., Kessl, J. J., Shkriabai, N., Dar, M. J., Engelman, A., & Kvaratskhelia, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805843200 · Cited by 129 · cited 8×
“LEDGF/p75 bridges between both individual subunits and two IN dimers to stabilize a tetrameric form of IN [16].”
BackgroundInfluentialSelf-citationBalakrishnan, M., Yant, S. R., Tsai, L., O’Sullivan, C., Bam, R. A., Tsai, A., Niedziela-Majka, A., Stray, K. M., Sakowicz, R., & Cihlar, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074163 · Cited by 126 · cited 10×
“The IN cross-linking assay was performed as described previously [41].”
BackgroundMethodResultInfluentialHIV-1 Integrase Inhibitors: A Decade of Research and Two Drugs in Clinical Trial
Johnson, A., Marchand, C., & Pommier, Y. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043388394 · Cited by 125 · cited 1×
“Three HIV-1 IN inhibitors, raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), are currently in clinical use [21,22].”
BackgroundIntegration target site selection by a resurrected human endogenous retrovirus
Brady, T., Lee, Y. N., Ronen, K., Malani, N., Berry, C. C., Bieniasz, P. D., & Bushman, F. D. (2009) · Genes & Development · doi:10.1101/gad.1762309 · Cited by 120 · cited 1×
“5 (matched random controls) have been described previously [78].”
BackgroundSelf-citationStatic and dynamic light scattering of biological macromolecules: what can we learn?
Murphy, R. M. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80153-x · Cited by 117
Dong, C., Janas, A. M., Wang, J., Olson, W. J., & Wu, L. J. (2007) · Journal of Virology · doi:10.1128/jvi.01081-07 · Cited by 117 · cited 2×
“qPCR and primers as described previously [71].”
MethodSelf-citationStructural biology of retroviral DNA integration
Li, X., Krishnan, L., Cherepanov, P., & Engelman, A. (2011) · Virology · doi:10.1016/j.virol.2010.12.008 · Cited by 112 · cited 1×
“contains the DDE catalytic triad that coordinates essential Mg ions, and the C-terminal domain (CTD) which contains an SH3-like fold (reviewed in [2]).”
BackgroundMarozsan, A. J., Fraundorf, E., Abraha, A., Baird, H., Moore, D., Troyer, R., Nankja, I., & Arts, E. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.20.11130-11141.2004 · Cited by 102
Sharma, A., Yilmaz, A., Marsh, K., Cochrane, A., & Boris-Lawrie, K. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002612 · Cited by 93 · cited 1×
“Supermix; Biorad) based qPCR using previously described [79] HIV-1 gag and gapdh: gag forward 59-GTAAGAAAAAGGCACAGCAAGCAGC, gag reverse 59-CATTTGCCCCTGGAGGTTCTG, gapdh forward 59-CATCAATGACCCCTTCATTGAC, and gapdh reverse 59-CGCCCCACTTGATTTTGGA.”
MethodSelf-citationLimón, A., Devroe, E., Lu, R., Ghory, H. Z., Silver, P. A., & Engelman, A. (2002) · Journal of Virology · doi:10.1128/jvi.76.21.10598-10607.2002 · Cited by 92
Molteni, V., Greenwald, J., Rhodes, D., Hwang, Y., Kwiatkowski, W., Bushman, F. D., Siegel, J. S., & Choe, S. (2001) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444901001652 · Cited by 89
Self-citationFeng, L., Sharma, A., Slaughter, A., Jena, N., Koh, Y., Shkriabai, N., Larue, R. C., Patel, P. A., Mitsuya, H., Kessl, J. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.443390 · Cited by 89 · cited 9×
“Structural and biochemical analyses have elucidated the underlying mechanism for HIV-1 A128T IN resistance to ALLINIs [40].”
BackgroundMethodInfluentialSelf-citationNdung'u, T., Renjifo, B., & Essex, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.11.4964-4972.2001 · Cited by 87 · cited 4×
“Thiswould beconsistentwiththecrystallographicresults(Figure2D)where Thr125wasfoundtohydrogenbondwithKF116,whereasAla125 wouldlacktheabilitytoformahydrogenbondwithKF116, resultingindecreasedpotency.”
MethodInfluentialTorre, V. S., Marozsan, A. J., Albright, J. L., Collins, K. R., Hartley, O., Offord, R. E., Quiñones‐Mateu, M. E., & Arts, E. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4868-4876.2000 · Cited by 85
Evolution of raltegravir resistance during therapy
Sichtig, N., Sierra, S., Kaiser, R., Däumer, M., Reuter, S., Schülter, E., Altmann, A., Fätkenheuer, G., Dittmer, U., Pfister, H., et al. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp153 · Cited by 83
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143
Métifiot, M., Vandegraaff, N., Maddali, K., Naumova, A., Zhang, X., Rhodes, D., Marchand, C., & Pommier, Y. (2011) · AIDS · doi:10.1097/qad.0b013e3283473599 · Cited by 80
Wares, M., Mesplède, T., Quashie, P. K., Osman, N., Han, Y., & Wainberg, M. A. (2014) · Retrovirology · doi:10.1186/1742-4690-11-7 · Cited by 77
Allosteric inhibition of HIV-1 integrase activity
Engelman, A., Kessl, J. J., & Kvaratskhelia, M. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.010 · Cited by 75
Self-citationAndrake, M. D., & Skalka, A. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29299 · Cited by 74
Gammaretroviral Integration into Nucleosomal Target DNA In Vivo
Roth, S. L., Malani, N., & Bushman, F. D. (2011) · Journal of Virology · doi:10.1128/jvi.00635-11 · Cited by 69 · cited 2×
“features was performed as described previously [20,77].”
BackgroundSelf-citationFunctional Oligomeric State of Avian Sarcoma Virus Integrase
Bao, K. K., Wang, H., Miller, J. K., Erie, D. A., Skalka, A. M., & Wong, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200550200 · Cited by 69 · cited 1×
“Thus, our DLS results reveal that the sizes of IN oligomers formed in the presence of KF116 significantly exceed that of tetrameric forms of the protein [55,56].”
BackgroundHIV integrase as a target for antiretroviral therapy
Hazuda, D. J. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283567309 · Cited by 63 · cited 1×
“Three HIV-1 IN inhibitors, raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), are currently in clinical use [21,22].”
BackgroundXing, L., Liang, C., & Kleiman, L. (2011) · Journal of Virology · doi:10.1128/jvi.02010-10 · Cited by 60 · cited 1×
“The initiation of reverse transcription from total viral RNA was measured using an in vitro HIV-1 reverse transcription reaction, which extends tRNA primer on viral RNA template by +6-nt, as described previously [82,83] with minor modifications.”
MethodJones, G. S., Yu, F., Zeynalzadegan, A., Hesselgesser, J., Chen, X., Chen, J., Jin, H., Kim, C. U., Wright, M., Geleziunas, R., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00984-08 · Cited by 57 · cited 4×
“The cytotoxcity assays were performed as described previously [45].”
BackgroundMethodInfluentialGuo, F., Saadatmand, J., Niu, M., & Kleiman, L. (2009) · Journal of Virology · doi:10.1128/jvi.00488-09 · Cited by 54
Jiang, J., Ablan, S. D., Derebail, S., Hercík, K., Soheilian, F., Thomas, J. A., Tang, S., Hewlett, I., Nagashima, K., Gorelick, R. J., et al. (2011) · Virology · doi:10.1016/j.virol.2011.09.012 · Cited by 52
Kessl, J. J., Li, M., Ignatov, M., Shkriabai, N., Eidahl, J. O., Feng, L., Musier-Forsyth, K., Craigie, R., & Kvaratskhelia, M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr581 · Cited by 52 · cited 7×
“Invitro experimentshavedemonstratedthatALLINIscanpotentlyinhibit boththeformationoftheSSCandtheLEDGF/p75bindingto theSSC[33].”
BackgroundInfluentialSelf-citationAn Allosteric Mechanism for Inhibiting HIV-1 Integrase with a Small Molecule
Kessl, J. J., Eidahl, J. O., Shkriabai, N., Zhao, Z., McKee, C. J., Hess, S., Burke, T. R., & Kvaratskhelia, M. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058883 · Cited by 50 · cited 1×
“In proof-of-concept studies [30] a small molecule inhibited IN activity in vitro by binding at the IN CCD dimer interface, stabilizing the interacting subunits and promoting aberrant IN multimerization.”
BackgroundSelf-citationA Homology Model of HIV-1 Integrase and Analysis of Mutations Designed to Test the Model
Johnson, B. C., Métifiot, M., Ferris, A., Pommier, Y., & Hughes, S. H. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.027 · Cited by 47
Shkriabai, N., Patil, S. S., Hess, S., Budihas, S. R., Craigie, R., Burke, T. R., Le Grice, S. F. J., & Kvaratskhelia, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400873101 · Cited by 43
Self-citationNucleoprotein Intermediates in HIV-1 DNA Integration Visualized by Atomic Force Microscopy
Kotova, S., Li, M., Dimitriadis, E. K., & Craigie, R. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.026 · Cited by 42 · cited 2×
“For example, atomic force microscopy experiments have revealed that IN tetramers in the stable synaptic complex have volumes ,220 nm(3) [55], which correspond to a diameter of ,7.”
BackgroundMultimodal mechanism of action of allosteric HIV-1 integrase inhibitors
Jurado, K. A., & Engelman, A. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.15 · Cited by 40
Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations
Varadarajan, J., McWilliams, M. J., & Hughes, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305066110 · Cited by 29 · cited 1×
“A recent report [61] has shown that the treatment of infected cells with suboptimal concentrations of RAL leads to aberrant HIV-1 integration, which results in significant rearrangements in the host genome.”
BackgroundDetermination of Diffusion Coefficients of Biological Macromolecules by Dynamic Light Scattering
Harding, S. E. (2003) · Humana Press eBooks · doi:10.1385/0-89603-232-9:97 · Cited by 12 · cited 1×
“Since the diffusion coefficient depends on the particle size and shape, DLS can be used to study particle aggregation [51,53,54].”
Method
Research works printed but not linked: 4
- Brown PO (1997) Integration. In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory. pp. 161–204.
- Fenwick CW, Tremblay S, Wardrop E, Bethell R, Coulomb R, <etal>et al</etal>.. (2011) Resistance Studies with HIV-1 Non-Catalytic Site Integrase Inhibitors. International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies. Los Cabos, Mexico. pp. A9.
- Tsantrizos YS, Boes M., Brochu C., Fenwick C., Malenfant E., Mason S., Pesant M. (2007) Inhibitors of Human Immunodeficiency Virus Replication. International Patent Application PCT/CA2007/000845. pp. 1–116.
- Yoakim C, Bailey MD, Bilodeau F, Carson RJ, Fader L, <etal>et al</etal>.. (2010) Inhibitors of human immunodeficiency virus replication. International Patent Application PCT/CA2010/000707. pp. 1–195.
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Lesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Structural and mechanistic bases for a potent HIV-1 capsid inhibitor
Bester, S. M., Wei, G., Zhao, H., Adu-Ampratwum, D., Iqbal, N., Courouble, V. V., Francis, A. C., Annamalai, A. S., Singh, P. K., Shkriabai, N., et al. (2020) · Science · doi:10.1126/science.abb4808 · Cited by 239
Self-citationHIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis
Kessl, J. J., Kutluay, S. B., Townsend, D., Rebensburg, S., Slaughter, A., Larue, R. C., Shkriabai, N., Bakouche, N., Fuchs, J. R., Bieniasz, P. D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.044 · Cited by 152
Self-citationStructure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Metadata
- Authors
- Sharma, A., Slaughter, A., Jena, N., Feng, L., Kessl, J. J., Fadel, H. J., Malani, N., Male, F., Wu, L., Poeschla, E., Bushman, F. D., Fuchs, J. R., & Kvaratskhelia, M.
- Affiliations
- The Ohio State University (US)
- Mayo Clinic (US)
- University of Pennsylvania (US)
- Corresponding author
- Kvaratskhelia, Mamuka
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-29
- Volume
- 10
- Issue
- 5
- Pages
- e1004171
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC4038613
- OpenAlex
- W2044894228
- Cited by
- 124
- References
- 80
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 9 · 2023: 10 · 2022: 14 · 2021: 13 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 8 · 2016: 15 · 2015: 9 · 2014: 5
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Gilead Sciences
- National Institutes of Health (AI062520, GM103368)
- National Institute of General Medical Sciences (P50GM103368)
- National Institute of Allergy and Infectious Diseases (R01AI062520, R01AI077344, R01AI104483, R01AI052845, R01AI110310, R21AI110270)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 integrase, integrase multimerization, LEDGF/p75, HIV-1 integration, antiviral drug design
- MeSH terms
- Antiviral Agents, Cell Line, Humans, Protein Binding, Quinolines, Virus Replication, HIV-1, Virus Integration, HIV Integrase, HIV Integrase Inhibitors, Intercellular Signaling Peptides and Proteins, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.